Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab

Data in patients with malignant melanoma, who have been previously treated with pembrolizumab as adjuvant therapy, show a reduction in pembrolizumab efficacy upon rechallenge. We examined this scenario in patients with non-metastatic renal cell carcinoma (RCC) eligible for adjuvant pembrolizumab aft...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Seminars in oncology 2022-04, Vol.49 (2), p.136-140
Hauptverfasser:	Flammia, Rocco S., Hoeh, Benedikt, Hohenhorst, Lukas, Sorce, Gabriele, Chierigo, Francesco, Panunzio, Andrea, Tian, Zhe, Saad, Fred, Leonardo, Costantino, Briganti, Alberto, Antonelli, Alessandro, Terrone, Carlo, Shariat, Shahrokh F., Graefen, Markus, Chun, Felix K.H., Montorsi, Francesco, Gallucci, Michele, Karakiewicz, Pierre I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Immunotherapy KEYNOTE-564 Kidney neoplasm Metastatic renal cell carcinoma Pembrolizumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!